Skip to main content

Table 3 Overall and race-specific frequencies of TMS1/ASC gene methylation in prostate-cancer patients and BPH controls, with age-adjusted odds-ratio estimates of the relative risk of prostate cancer associated with TMS1/ASC gene methylation.

From: Methylation mediated silencing of TMS1/ASC gene in prostate cancer

 

Number and (%) of tissues with TMS1/ASC methylation

Age-adjusted odds ratio* (95% CI)

 

Patients

Prostate Cancer

Control (BPH)

 

P-value

All

42/66 (63.6)

12/34 (35.3)

3.7 (1.4 – 9.4)

0.008

Blacks

14/21 (66.7)

7/12 (58.3)

1.1 (0.2 – 5.5)

0.91

Whites

28/45 (62.2)

5/22 (22.7)

7.6 (2.1 – 27.3)

0.002

  1. * For the overall odds ratio estimate, we modeled the logit of the probability of being a case (p), as a function of TMS1/ASC gene methylation and age: ln [p/(1-p)] = b0 + b1 × TMS1/ASC + b2 × Age. For the race-specific age-adjusted odds-ratio estimates, the following model was fitted: ln [p/(1-p)] = b0 + b1 × TMS1/ASC + b2 × Age + b3 × Race + b4 × TMS1/ASC × Race. The interaction term TMS1/ASC*Race was marginally significant (p = 0.068).
Back to article page

Molecular Cancer

ISSN: 1476-4598